ComplianceFDA DSCSA Interoperable Tracing
FDA’s Drug Supply Chain Security Act interoperability enforcement has been live since November 2024, and wholesalers now have six weeks to remediate any electronic tracing gaps before FY2025 inspection cycles ramp up.
Fact-checked and reviewed — Kodi C.
FDA's November 27, 2024 compliance policy ended the stabilization period for DSCSA interoperable electronic tracing. Manufacturers, repackagers, wholesale distributors, and dispensers must now exchange transaction information, histories, and statements electronically and provide serialized package-level data within 24 hours of regulatory requests. This milestone represents the culmination of over a decade of pharmaceutical supply chain security legislation, fundamentally transforming how prescription drugs are tracked from manufacturer to patient.
DSCSA Legislative Background
The Drug Supply Chain Security Act was enacted in 2013 as part of the Drug Quality and Security Act, establishing a ten-year setup timeline for interoperable electronic tracing of prescription drugs. The law replaced a patchwork of state pedigree requirements with a uniform federal standard, creating consistency across the pharmaceutical supply chain while enabling industry collaboration on setup.
DSCSA setup proceeded through multiple phases with increasing requirements. Initial phases focused on lot-level tracing and basic transaction documentation. The final phase, originally targeted for November 2023 but extended to November 2024, requires package-level serialization and interoperable electronic data exchange. This phase enables granular tracking of individual drug packages throughout the supply chain.
The stabilization period that ended in November 2024 provided industry additional time to achieve interoperability across trading partners. During stabilization, FDA exercised enforcement discretion for good-faith compliance efforts while the industry resolved technical and operational challenges. With stabilization ended, full enforcement of interoperability requirements is now in effect.
Serialization and Tracing Requirements
Package-level serialization assigns unique identifiers to individual drug packages using standardized formats. Serial numbers, combined with product identifiers including NDC, lot number, and expiration date, enable tracking of specific packages through the supply chain. Serialization must be applied at the manufacturer or repackager level before products enter distribution.
Transaction information flows with products as they move through the supply chain. Each transfer requires electronic transmission of transaction data including product identifiers, serial numbers, shipment dates, and party identifications. Receiving parties must verify transaction data against physical product before accepting shipments.
Transaction histories provide the complete chain of ownership for products. When products reach dispensers or when regulatory requests are made, the full transaction history must be available within 24 hours. This requirement demands strong data management and rapid query capabilities across trading partner systems.
Interoperability Standards and Implementation
EPCIS (Electronic Product Code Information Services) provides the technical foundation for DSCSA interoperability. EPCIS standards define message formats and business processes for exchanging serialization and tracing data between trading partners. Implementation typically uses EPCIS versions 1.2 or 1.3, with industry adoption of common usage guidelines ensuring consistency.
Trading partner connectivity requires establishing technical interfaces for EPCIS message exchange. Direct connections, value-added networks, and solution provider platforms provide connectivity options with varying complexity and cost profiles. Trading partners must validate interoperability through testing before production setup.
Master data management underlies successful DSCSA setup. Product master data including GTINs, NDCs, and product hierarchies must be accurate and synchronized across trading partners. Party master data including GLNs and business relationships must similarly be maintained. Data quality issues are a leading cause of DSCSA transaction failures.
Verification and Exception Management
Product verification capabilities enable trading partners to confirm product authenticity. Verification requests can be initiated for suspect products, returns processing, or routine sampling. Verification systems must respond within 24 hours with package-level status information. High verification volumes require automated processing capabilities.
Suspect product investigations trigger when verification fails or other indicators suggest potential illegitimacy. Investigation procedures must be documented and consistently followed. Quarantine protocols prevent suspect products from further distribution pending investigation completion. Investigation outcomes must be documented and retained.
Illegitimate product handling requires notification to FDA and trading partners when products are determined to be counterfeit, diverted, stolen, or otherwise illegitimate. Notification timelines are specified in regulation. Products must be dispositioned appropriately, typically through destruction with documentation.
Saleable Returns Processing
Saleable returns present particular DSCSA complexity as products reverse direction through the supply chain. Returns processing requires verification of product authenticity and transaction history before products can be returned to saleable inventory. Automated returns processing reduces manual handling and compliance risk.
Mixed lot returns add complexity to verification and tracing. Returns from dispensers may include products from multiple original shipments with different transaction histories. Systems must match returned products to original transactions and maintain accurate histories through the returns process.
Returns policies and procedures should address DSCSA compliance requirements explicitly. Credit processing, inventory management, and quality procedures should integrate with serialization systems. Training for returns processing staff should cover DSCSA requirements and exception handling.
Inspection Readiness
FDA inspection expectations have evolved with full DSCSA setup. Inspectors may request demonstration of interoperability capabilities, verification response times, and exception management procedures. System access, documentation, and knowledgeable personnel should be available to support inspections.
Inspection binders should include system documentation, trading partner agreements, standard operating procedures, and evidence of compliance activities. Transaction logs, verification records, and investigation documentation should be readily accessible. Role-based access controls and audit trails show data integrity.
Mock inspections validate readiness for regulatory examination. Internal audits or third-party assessments can identify gaps in documentation, procedures, or system capabilities. Remediation should be focus ond based on compliance risk and inspection likelihood.
Third-Party Logistics Provider Considerations
Third-party logistics providers (3PLs) play significant roles in pharmaceutical distribution and must comply with DSCSA requirements. 3PL responsibilities include maintaining transaction data, responding to verification requests, and managing exceptions for products in their custody. Contractual arrangements should clearly allocate DSCSA responsibilities.
Data exchange between product owners and 3PLs requires careful process design. Transaction data must flow accurately as products move into and out of 3PL facilities. Verification requests may be routed through 3PL systems or directly to product owners depending on setup approach.
3PL selection and oversight should include DSCSA capability assessment. Due diligence should evaluate systems, processes, and compliance track record. Ongoing monitoring should verify continued compliance and identify emerging issues.
Analytics and Continuous Improvement
DSCSA data provides valuable insights beyond compliance requirements. Transaction data analysis can identify distribution patterns, inventory improvement opportunities, and potential diversion indicators. Verification data can highlight suspect product trends and trading partner performance.
Key performance indicators should track DSCSA compliance and operational efficiency. Transaction success rates, verification response times, and exception volumes provide operational visibility. Trend analysis identifies improvement opportunities and emerging risks.
Continuous improvement processes should address recurring exceptions and system limitations. Root cause analysis of transaction failures, verification delays, and investigation outcomes drives process refinement. Industry collaboration through associations and working groups shares good practices and addresses common challenges.
Continue in the Compliance pillar
Return to the hub for curated research and deep-dive guides.
Latest guides
-
Third-Party Risk Oversight Playbook
Operationalize OCC, Federal Reserve, EBA, and MAS outsourcing expectations with lifecycle controls, continuous monitoring, and board reporting.
-
Compliance Operations Control Room
Implement cross-border compliance operations that satisfy Sarbanes-Oxley, DOJ guidance, EU DORA, and MAS TRM requirements with verifiable evidence flows.
-
ESG Assurance Operating Guide
Deploy credible ESG assurance across CSRD, SEC climate disclosure, and ISSA 5000 requirements with regulator-aligned controls, data governance, and audit-ready evidence.
Coverage intelligence
- Published
- Coverage pillar
- Compliance
- Source credibility
- 86/100 — high confidence
- Topics
- Pharmaceutical compliance · Serialization · Supply chain security
- Sources cited
- 3 sources (fda.gov, iso.org)
- Reading time
- 6 min
Source material
- FDA Compliance Policies for the Drug Supply Chain Security Act — U.S. Food and Drug Administration
- FDA DSCSA Guidances for Industry — U.S. Food and Drug Administration
- ISO 37301:2021 — Compliance Management Systems — International Organization for Standardization
Comments
Community
We publish only high-quality, respectful contributions. Every submission is reviewed for clarity, sourcing, and safety before it appears here.
No approved comments yet. Add the first perspective.